Pancreatic Cancer UK is calling for greater investment in research funding for pancreatic cancer as new data reveals that just three percent of patients with the most common form will survive beyond five years.
Ninety-five percent of people with pancreatic cancer are diagnosed with pancreatic ductal adenocarcinoma (PDAC), but because of the way that data is published true survival rates for this type of the disease were previously not known.
This is because information about PDAC was previously published together with that for another type called pancreatic neuroendocrine tumours (PNET), which has a far higher survival. Therefore the true survival for PDAC appeared better than it really is; the most recent statistics for England having shown a five-year survival rate of less than seven percent of patients.
Read more: http://www.pharmatimes.com/news/pancreatic_cancer_survival_much_lower_than_thought,_research_finds_1240926